Dec 6 2010
Asuragen, Inc. announced today that it has entered into an exclusive agreement with Novartis to develop worldwide Armored RNA Quant® (ARQ) BCR-ABL1 RNA International Scale (IS) Calibrators and laboratory software reporting tools, intended to aid laboratories with standardization of BCR-ABL1 RT-qPCR testing to the International Scale. As part of this agreement, Asuragen will develop and, if successful, distribute the ARQ BCR-ABL1 IS RNA Calibrators and software reporting tools to laboratories globally directly or through its distributors.
“Our development of the BCR-ABL1 RNA IS Calibrators and software tool leverages both our expertise in molecular diagnostics assay development and our proprietary Armored RNA® technology. We are pleased to be working with Novartis in order to develop a standardization of BCR-ABL1 molecular testing for the entire global testing community”
The BCR-ABL1 RNA IS Calibrators are intended to be compatible with several widely used assays, including both commercially available and laboratory developed tests (LDTs). In addition to facilitating the standardization of BCR-ABL1 RT-qPCR results to the International Scale, the RNA Calibrators are also expected to provide unmatched internal and external assay calibration. The software reporting tool is expected to help standardize how BCR-ABL1 RT-qPCR results are reported according to the IS.
"Our development of the BCR-ABL1 RNA IS Calibrators and software tool leverages both our expertise in molecular diagnostics assay development and our proprietary Armored RNA® technology. We are pleased to be working with Novartis in order to develop a standardization of BCR-ABL1 molecular testing for the entire global testing community," said Rollie Carlson, President, Asuragen, Inc.
SOURCE Asuragen, Inc.
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions